Notably, bispecific antibodies targeting both PD-1/PD-L1 and TGF-β named YM101 and M7824 were developed and achieved superior effects against cancers by overcoming the anti-PD1/PD-L1 drug resistance induced by TGF-β (52–54). Here, PDCD1 is linked to cancer.